ReclutandoNCT05714085
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
Fase 2 / Fase 3Merck Sharp & Dohme LLC
Condiciones: Heart Failure, Left Ventricular Systolic Dysfunction
Sedes en Guadalajara: CINVEC Medica ( Site 1814)
Ver registro oficial ↗ReclutandoNCT06424288
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Fase 3Boehringer Ingelheim
Condiciones: Heart Failure
Sedes en Guadalajara: CICEJ Centro de Investigacion Clinica Endocrinologica de Jalisco S.C. · Salud Cardiovascular
Ver ficha informativaReclutandoNCT06935370
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Fase 3Boehringer Ingelheim
Condiciones: Heart Failure
Sedes en Guadalajara: Cardiologia Clinica e Intervencionista
Ver registro oficial ↗ReclutandoNCT07037433
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Fase 3Amgen
Condiciones: Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Sedes en Guadalajara: Private Practice Dr. Francisco Padilla Padilla
Ver registro oficial ↗ReclutandoNCT07064473
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Fase 3Boehringer Ingelheim
Condiciones: Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Sedes en Guadalajara: Instituto Jalisciense de Investigacion En Diabetes Y Obesidad Sc · Virgen Cardiovascular Research SC.
Ver ficha informativaReclutandoNCT07157774
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Fase 3Eli Lilly and Company
Condiciones: Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Sedes en Guadalajara: Centro de Investigación Clínica y Medicina Traslacional (CIMeT) · Diseno y Planeacion en Investigacion Medica - Guadalajara - Calle Amado Nervo · Instituto Jalisciense de Investigacion en Diabetes y Obesidad
Ver registro oficial ↗ReclutandoNCT07241390
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Fase 3Eli Lilly and Company
Condiciones: Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
Sedes en Guadalajara: Diseno y Planeacion en Investigacion Medica · Instituto Jalisciense de Investigacion en Diabetes y Obesidad · Unidad de Investigación Clínica y Atención Médica HEPA S.C.
Ver registro oficial ↗ReclutandoNCT07567001
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Fase 3Novo Nordisk A/S
Condiciones: Obesity, Heart Failure
Sedes en Guadalajara: Consultorio Privado Dr Gabriel Arturo Ramos · Consultorio Privado Dr. Francisco Padilla
Ver ficha informativaReclutandoNCT07794579
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Fase 3Eli Lilly and Company
Condiciones: Overweight, Prediabetic State, Prehypertension
Sedes en Guadalajara: Diseno y Planeacion en Investigacion Medica - Guadalajara - Calle Amado Nervo
Ver registro oficial ↗ReclutandoNCT07797335
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
Fase 3Novo Nordisk A/S
Condiciones: Type 2 Diabetes, Cardiovascular Risk
Sedes en Guadalajara: Diseño y Planeación en Investigación Médica S.C. · Instituto Jalisciense de Investigación en Diabetes y Obesidad · Centro de Investigacion Clinica Endocrinologica de Jalisco
Ver ficha informativa